VivoSeq
Immunology

Immunodeficiency Disease

19

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Immunodeficiency Disease is an emerging landscape with 19 programs across 10 companies. The most active players are Octapharma, Takeda, CSL Behring. 5 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

60/100

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Octapharma logo

Octapharma

5 programs

Phase 3Takeda logo

Takeda

4 programs

Phase 3CSL Behring logo

CSL Behring

1 program

Phase 3Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

1 program

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

ApprovedNovartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

20

clinical trials

Completed13 · 65%
Unknown status3 · 15%
Terminated1 · 5%
Available1 · 5%
Active, not recruiting1 · 5%
Recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
Recruiting·Takeda logoTakeda·Phase 3·NCT06076642·39 enrolled
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Active, not recruiting·Octapharma logoOctapharma·Phase 3·NCT04640142·50 enrolled
Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases
Completed·Octapharma logoOctapharma·Phase 3·NCT03939533·64 enrolled
Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Completed·AADMA Biologics, Inc.·Phase 3·NCT01814800·59 enrolled
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Completed·BBaxalta now part of Shire·Phase 3·NCT04346108·17 enrolled
A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants
Completed·Takeda logoTakeda·Phase 3·NCT05513586·15 enrolled
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
Completed·Takeda logoTakeda·Phase 3·NCT05150340·16 enrolled
CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL
Completed·Octapharma logoOctapharma·Phase 3·NCT03907241·27 enrolled
Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
Completed·BBio Products Laboratory·Phase 3·NCT00278954·50 enrolled
A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases
Completed·Octapharma logoOctapharma·Phase 3·NCT01012323·51 enrolled
Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases
Completed·BBio Products Laboratory·Phase 3·NCT01884311·38 enrolled
Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Completed·BBio Products Laboratory·Phase 3·NCT01963143·48 enrolled
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
Completed·Takeda logoTakeda·Phase 3·NCT04842643·12 enrolled
Study to Evaluate the Efficacy, Tolerability and Safety of Octanorm in Patients With Primary Immunodeficiency Diseases
Completed·Octapharma logoOctapharma·Phase 3·NCT03988426·25 enrolled
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
Completed·Takeda logoTakeda·Phase 2/3·NCT05755035·65 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)